3Stansfeld SA, Roberts R, Foot SP. Assessing the validity of the SF--k36 general health survey[J]. Qual Life Res,1997,6:217.
4Guyatt GH. Measurement of health-related quality of life in heart failure [J]. J Am Coll Cardiol, 1993, 22:185A--191A.
5Rector T, Kubo S, Cohn J. Patients self-assessment of their congestive heart failure. Part 2 : content, reliability and validity of a new measure, the Minnesota living with heart failure questionnaire [J]. Heart Failure, 1987, 3: 198--209.
6Rector T, Cohn J. Assessment of patient outcome with the Min- nesota living with heart failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan [J]. Am Heart J, 1992, 124: 1017--1025.
7Rector T, Kubo S, Cohn J. Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo[J]. Am J Cardiol, 1993,71 : 1106-- 1107.
8Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas city cardiomyopathy questionnaire: a new health status measure for heart failure[J].J Am Coll Cardial, 2000, 35, 1245--1255.
9O'Leary CJ, Jones PW. The left ventricular dysfunction questionnaire (LVD-- 36) : reliability, validity, and responsiveness [J].Heart, 2000, 83: 634--640.
10Rector, Anand, Cohn. Relationships between clinical assessments and patients perceptions of the effects of heart failure on their [J]. Quality of Life, 2006, 12 (2): 87--92.
4Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure [J]. Eur Heart J, 2001, 22: 1527-1560.
5Cleland JG, Coletta AP, Lammiman M, et al.Clinical trials update from the European society of cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-Ⅲ, S-ICD, ISSUE- 2, STRIDE- 2, SOFA, IMAGINE. PREAMI, SIRIUS-Ⅱ and ACTIVE [J]. Eur J Heart Fail, 2005, 7 (6): 1070-1075.
6Willenheimer R, van Veldhuisen DJ, Ponikowski P, et al. CIBIS-Ⅱ stering committee and investigators: Betablocker treatment before angiotensin-converting enzyme inhibitor therapy in newly diagnosed heart failure [J]. J Am Coll Cardiol, 2005, 46 (1): 182.
7Leizorovicz A, Lechat P, Cucherat M, et al, Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies-CIBIS and CIBIS Ⅱ, Cardiac insufficiency bisoprolol study [J]. Am Heart J, 2002, 143 (2), 301-307.
8Deedwania PC, Giles TD, Klibaner M, et al. MERIT-HF study group. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF [J]. Am Heart J, 2005, 149 (1): 159-167.
9Packer M, Coats AJS, Fowler MB. et al. For the carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure [J]. N EnglJ Med, 2001, 344: 1651-1658.
10Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hy-perkalemia after publication of the randomized aldactone evaluation study[J]. N EnglJ Med, 2004, 351:543-551.
8Peterson ED,Roe MT,Mulgund J,et al.Association between hospital process pedormance and outcomes among patients with acute corcnary syndromes[J].JAMA,2006,295(16):1912-1920.
9WILSON I B,CLEARLY P D. Linking clinical vailables with health-related quality of life : A conception model of patient out comes [ J ]. JAMA, 1995,273 ( 1 ) : 60.
10KARMILOVICH S E. Burden and stress associated with spousal caregivng for individuals with heart failure [J ]. Prog Cardiovasc Nurs, 1994,9 ( 1 ) : 33-38.
